- Home
- OGI vs LCTX Comparison
OGI vs LCTX Comparison
Compare OGI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- LCTX
- Stock Information
- Founded
- OGI 2013
- LCTX 1990
- Country
- OGI Canada
- LCTX United States
- Employees
- OGI N/A
- LCTX N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- LCTX Health Care
- Exchange
- OGI Nasdaq
- LCTX Nasdaq
- Market Cap
- OGI 180.7M
- LCTX 107.3M
- IPO Year
- OGI N/A
- LCTX N/A
- Fundamental
- Price
- OGI $1.45
- LCTX $1.00
- Analyst Decision
- OGI
- LCTX Strong Buy
- Analyst Count
- OGI 0
- LCTX 5
- Target Price
- OGI N/A
- LCTX $4.20
- AVG Volume (30 Days)
- OGI 601.6K
- LCTX 4.2M
- Earning Date
- OGI 08-12-2025
- LCTX 08-07-2025
- Dividend Yield
- OGI N/A
- LCTX N/A
- EPS Growth
- OGI N/A
- LCTX N/A
- EPS
- OGI 0.10
- LCTX N/A
- Revenue
- OGI $135,031,829.00
- LCTX $9,557,000.00
- Revenue This Year
- OGI $50.30
- LCTX N/A
- Revenue Next Year
- OGI $16.01
- LCTX $232.66
- P/E Ratio
- OGI $14.17
- LCTX N/A
- Revenue Growth
- OGI 20.49
- LCTX 19.42
- 52 Week Low
- OGI $0.85
- LCTX $0.37
- 52 Week High
- OGI $2.08
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- OGI 58.18
- LCTX 66.90
- Support Level
- OGI $1.36
- LCTX $0.93
- Resistance Level
- OGI $1.50
- LCTX $1.06
- Average True Range (ATR)
- OGI 0.06
- LCTX 0.11
- MACD
- OGI 0.01
- LCTX -0.00
- Stochastic Oscillator
- OGI 80.00
- LCTX 70.00
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.